Jazz Pharmaceuticals (JAZZ)

Executive Summary

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on rare diseases, with approved products in sleep disorders (Xyrem/Xywav), epilepsy (Epidiolex), and oncology (Vyxeos, Ziihera). The company has a market capitalization of $11.3 billion and nine commercial products. Key pipeline assets include lurbinectedin in Phase 1/2 for Ewing sarcoma and a Phase 2/3 trial of Vyxeos combined with chemotherapy for acute myeloid leukemia. Jazz continues to optimize its portfolio through label expansions and new indications, while managing patent cliffs for its sleep franchise. The company's strong cash flow supports business development and pipeline investments to sustain long-term growth.

Upcoming Catalysts (preview)

• H2 2026Lurbinectedin Phase 1/2 data for Ewing sarcoma30% success
• Q1 2027Vyxeos+chemo Phase 2/3 results in AML40% success
• 2026Epidiolex label expansion for new epilepsy indications50% success